General Information of Drug (ID: DMEVARK)

Drug Name
GSK561679 Drug Info
Synonyms
VERUCERFONT; 885220-61-1; GSK561679; GSK561679A; UNII-X60608B091; GSK 561679A; NBI-77860; X60608B091; GSK561679;3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]pyrazolo[1,5-a]pyrimidin-7-amine; NBI 77860; Verucerfont [USAN:INN]; GSK 561679; GSK-561679; Verucerfont (USAN/INN); Verucerfont,GSK561679; SCHEMBL205309; CHEMBL1287935; EX-A1718; BDBM50417503; ZINC34661169; SB17107; CS-8099; DB12512; KB-77609; HY-14875; AC-30339; D09695
Indication
Disease Entry ICD 11 Status REF
Alcohol dependence 6C40.2 Phase 2 [1]
Major depressive disorder 6A70.3 Phase 2 [1]
Cross-matching ID
PubChem CID
11596613
CAS Number
CAS 885220-61-1
TTD Drug ID
DMEVARK

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Preclinical Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Telavancin DM58VQX Staphylococcus infection 1B5Y Approved [3]
Pexacerfont DMBJ15R Anxiety disorder 6B00-6B0Z Phase 2/3 [4]
SSR125543 DMGJEB8 Anxiety disorder 6B00-6B0Z Phase 2 [5]
ONO-2333Ms DMOT0WR Anxiety disorder 6B00-6B0Z Phase 2 [6]
Tildacerfont DMAB8LH Congenital adrenal hyperplasia 5A71.01 Phase 2 [7]
GSK586529 DM5E9LX Anxiety disorder 6B00-6B0Z Phase 1 [2]
GW876008 DMAXRBI Irritable bowel syndrome DD91.0 Discontinued in Phase 2 [4]
CP-316,311 DMZ76EM Major depressive disorder 6A70.3 Discontinued in Phase 2 [4]
CRA1000 DMWMBIV Anxiety disorder 6B00-6B0Z Preclinical [3]
NBI-37582 DM3JY2N Anxiety disorder 6B00-6B0Z Terminated [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Corticotropin-releasing factor receptor 1 (CRHR1) TT7EFHR CRFR1_HUMAN Antagonist [2]

References

1 ClinicalTrials.gov (NCT01187511) Effects of Corticotropin-Releasing Hormone Receptor 1 (CRH1) Antagonism on Stress-Induced Craving in Alcoholic Women With High Anxiety. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
3 A review of drug options in age-related macular degeneration therapy and potential new agents. Expert Opin Pharmacother. 2006 Dec;7(17):2355-68.
4 Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
5 Pharma & Vaccines. Product Development Pipeline. April 29 2009.
6 Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism. Drug Alcohol Depend. 2013 Mar 1;128(3):175-86.
7 Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia. Eur J Endocrinol. 2021 Nov 30;186(1):R1-R14.
8 CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.